Synta announces advancement of ganetespib into phase 3 extension of AML LI-1 study
Synta announced advancement of ganetespib into the Phase 3 extension of the AML LI-1 trial. AML LI-1 is a multicenter, randomized Phase 2/3 clinical study evaluating novel treatment regimens, including the combination of ganetespib with low dose cytarabine, in newly diagnosed elderly patients. July 22, 2014